This structural damage cannot be reversed by thawing, and the medication loses its ability to bind effectively to GIP and GLP-1 receptors, compromising its glucose-lowering and weight-reducing effects
Compounded tirzepatide is a synthetic, dual-acting glucagon-like peptide-1 (GLP-1) and GIP receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Digestive symptoms such as nausea, stomach discomfort, or mild indigestion may occur when treatment begins
Rushing guarantees worse side effects at the next tier
Similarly, patients with liver issues should have their health provider monitor their condition closely